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Abstract. New data have been accumulated in the scientific 
literature in recent years which allow a more adequate risk 
assessment of selenium with reference to human health. This 
new evidence comes from environmental studies, carried out 
in populations characterized by abnormally high or low sele-
nium intakes, and from high-quality and large randomized 
controlled trials with selenium recently carried out in the US 
and in other countries. These trials have consistently shown no 
beneficial effect on cancer and cardiovascular risk, and have 
yielded indications of unexpected toxic effects of selenium 
exposure. Overall, these studies indicate that the minimal 
amount of environmental selenium which is source of risk 
to human health is much lower than anticipated on the basis 
of older studies, since toxic effects were shown at levels of 
intake as low as around 260 µg/day for organic selenium and 
around 16 µg/day for inorganic selenium. Conversely, popula-
tions with average selenium intake of less than 13-19 µg/day 
appear to be at risk of a severe cardiomyopathy, Keshan 
disease. Overall, there is the need to reconsider the selenium 
standards for dietary intake, drinking water, outdoor and 
indoor air levels, taking into account the recently discovered 
adverse health effects of low-dose selenium overexposure, 




2. The epidemiologic evidence
3. Adequacy of environmental standards
1. Introduction
The health risk assessment of environmental selenium, 
concerning both abnormally low and high intakes, and the 
related regulatory guidelines are generally based on ‘old’ 
evidence, since they have generally been unable to take into 
consideration the most recent epidemiologic and biochemical 
evidence, and particularly the recent results of large and 
well-designed randomized controlled trials (RCTs) (1-3). The 
results of these trials, in connection with biochemical and 
toxicological studies, have shed new light on this relevant 
public health issue. This has happened with reference to both 
the upper and the lower limits of selenium intake, which have 
been so far based in all the assessment on observational studies 
carried out in seleniferous Chinese areas during the 1980s (4,5). 
The availability of the experimental studies (the trials) is of 
particular importance, since they allowed to rule out the key 
issue of (unmeasured) confounding, typically affecting most of 
observational studies with the possible only exception of the so 
called ‘natural experiments’ (6). In addition, the recent observa-
tional and experimental studies made it possible to investigate 
different populations with reference to age, genetic background 
and life-style factors, also allowing to test the health effect of 
selective exposure to specific selenium compounds, such as 
inorganic haxavalent selenium (selenate) and an organic form, 
selenomethionine. This is particularly important since there is 
growing evidence of the key importance of the specific selenium 
forms in influencing the biological activity of this element, with 
reference to both its toxicological and nutritional effects (7-11).
2. The epidemiologic evidence
A very large number of epidemiologic studies assessed the 
relation between chronic exposure to environmental selenium 
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and human health. The studies on this issue frequently inves-
tigated the effect on human health of unusually low or high 
environmental exposures to selenium, due to an abnormal 
selenium content in soil, locally produced foods and drinking 
water, or following combustion of coal with high selenium 
content (5,12,13). In addition, the scientific literature encom-
passes a large number of nutritional epidemiology studies 
on the long-term health effects of selenium carried out in 
populations living in non-seleniferous regions and countries. 
These studies include experimental investigations (random-
ized controlled trials) and observational studies, the latter 
characterized by case-control, cohort, cross-sectional and 
ecologic design and being characterized by a far weaker 
ability compared with trials in addressing the selenium and 
health relation (1,14,15). While the entire review of this huge 
literature goes beyond the possibility of this report, we aim 
at briefly updating the evidence generated by the most recent 
environmental and nutritional studies on the human health 
effects of selenium, the biological plausibility of this relation, 
an overview of the challenges that these studies and their inter-
pretation pose, and finally their implications on the adequacy 
of current environmental selenium standards. Our update of 
this issue starts from the comprehensive assessments of sele-
nium exposure carried out by the US Institute of Medicine in 
2000 (4) and by a World Health Organization (WHO) working 
group in 2004 (16).
Studies in populations living in unusually high and low sele-
nium environments. A large number of environmental studies 
which investigated the health effects of unusually high or low 
selenium areas have been published, as summarized in Table I. 
These studies have also substantially contributed to the PubMed-
indexed papers on the epidemiology of selenium and human 
health in addition to the previous papers (Fig. 1), adding relevant 
data to our understanding of the health effects of selenium in 
humans. Some of these studies have been published after the 
2000 Institute of Medicine selenium assessment (4), consider-
ably extending the limited evidence previously available on the 
basis of a few ʻoldʼ Chinese studies. This literature includes the 
investigation of health effects of high-selenium environment 
in South and North America, India, China, and Italy. The high 
content of selenium in these areas, in most cases of geological 
origin, has induced unusually high levels of selenium in locally 
grown foodstuffs and occasionally in outdoor air and in drinking 
water, thus increasing human exposure to the element. However, 
systematic investigations of the health effects of such exposures 
are unfortunately limited, and in most cases they came from 
cross-sectional studies, and very rarely from studies with a 
more adequate design, such as case-control and particularly 
cohort studies. In addition, the observational design of these 
studies induces in most cases a major concern, the potential bias 
arising from unmeasured (dietary and life-style) confounding, 
in addition to the potential issue of exposure misclassifica-
tion. Moreover, health endpoints were generally different in 
these studies, thus not allowing their systematic analysis (and 
meta-analysis) in the different populations. Finally, in several 
cases the small number of exposed subjects made it impossible 
to compute statistically stable estimates, and this lack of preci-
sion hampered the detection of potential health effects of such 
abnormally low and high exposures to environmental selenium.
Overall, these studies have yielded an indication that the 
extremely low selenium intake, in the order of <10-15 µg/day, 
may increase the risk of a severe cardiomyopathy named 
‘Keshan disease’ (17-20), while high selenium intake may 
have unfavorable effects on the endocrine system and particu-
larly on the thyroid status (21), and increase the risk of type 
2 diabetes (3,22,23), some specific cancers such as melanoma 
and lymphoid cancers (24-26), and nervous system distur-
bances including alterations in visual evoked potentials (27) 
and excess risk of amyotrophic lateral sclerosis (26,28).
Figure 1. Number of hits (on the horizontal axis) generated by PubMed search on January 4, 2017 with the MeSH terms ‘selenium’ and ‘humans’ and (‘epi-
demiology’ or ‘epidemiologic methods’) linked to specific diseases (dark plus light gray areas). Those additionally linked with the additional MeSH terms 
‘environment’ or ‘risk’ or ‘assessment and government regulation’ are in light gray (percentage on the total hits on the vertical axis).
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Table I. Overview of studies on the health effects of environmental selenium.
A, Studies published up to 2000
Area Population study Laboratory indications Health effects
Colorado A community of 120 households Higher urinary levels of Se No significant differences between
Tsongas 1977 receive tap water containing in the exposed group.  exposed and unexposed groups.
and 1978 (99,100) unusually high Se levels Much higher urinary Se Lack of association between
 (50-125 µg/l). Eighty-six levels of women with a spontaneous abortion and Se
 persons participate in this study. history of miscarriage. exposure through drinking water
   in women experiencing
   miscarriages in that community.
Mianning,  This study was carried out among Not assessed. In 1974, there were 13.5% cases
Sichuan Province, children of susceptible age  of Keshan disease among control
China (1-9 years) in 1974 and 1975.   group, while only 2.2%
Keshan Disease  One half of the children were  subjects fell ill in the
Research Group given sodium selenite and the  Se supplemented group.
of the Chinese other half placebo. The  In 1975, there were 9.5% cases
Academy of subjects took sodium selenite  of Keshan disease in the control
Medical Sciences, once a week, the dosage being  group, while only 1.0%
Bejing 1979 (18) 1-5 year old 0.5 mg, 6-9 year old  cases in the treated group.
 1.0 mg and above 11 years 2.0 mg.  In 1976 and 1977 there were
 In 1976-1977 all the subjects  respectively 0.32% and
 were given sodium selenite,   0 cases of Keshan disease
 no controls were used.  among treated subjects.
Milan, New  Thirty-three residents in a small High Se exposure through Not assessed.
Mexico community consumed drinking drinking water was
Valentine 1980, water from personal wells associated with lower
1988 and 1997 containing very high levels blood glutathione
(101-103) of Se (26-1800 µg/l). peroxidase activity.
Enshi, Hubei Endemic disease in 1961 in parts In high Se area of chronic The tissues most affected
Province, China of the population of Enshi selenosis, hair Se level during the time of heavy
Yang 1983 (55) county. During 1961-1964, the  was 32.2 µg/g and blood prevalence were loss of hair
 morbidity was almost 50% in the Se level was 3.2 µg/ml. and nails, skin lesions, tooth
 248 inhabitants of the most  decay and abnormalities of the
 affected villages.  nervous system like peripheral
 Daily dietary intake of Se  anesthesia, acroparaesthesia
 of 4.99 mg.  and pain in the extremities.
Red Butte and  Fifty residents in three Blood and hair Se levels were Little evidence of a relation
Jade Hills in  communities with unusually high  higher in exposed subjects between Se exposure and risk
Wyoming and Se content in their drinking water but the differences were small for a number of gastrointestinal,
Grants in New  supply systems (respectively 494,  despite the large difference in cutaneous and nervous system
Mexico 194, 327 µg/l) were compared water Se levels. Differences in conditions emerged.
Valentine 1987 to 99 individuals from Nevada urine Se concentrations between Higher prevalence of diarrhea, 
(104) and Wyoming communities exposed and unexposed subjects neurological diseases in the
 which had drinking water with were much larger, though most exposed communities
 3 and 2 µg/l Se, respectively. still less marked than the of Grants and Red Butte.
  difference in water Se content.
South Dakota and Inhabitants (142) of areas Se levels assessed using whole No effect of Se exposure on the
Wyoming with endemic Se overexposure blood, serum, toenail, urine risk of paresthesias was found
Longnecker recruited over a 2-year period.  and dietary intake. (it actually decreased). By contrast, 
1991 (105) About half of the 142 free-living  an increased risk of lethargy
 subjects had selenium intake  emerged since the OR of having
 greater than 200 µg/day.  this sign more frequently than the
   median for an increase of one
   standard deviation of whole blood, 
   toenails or dietary Se was equal to
   1.41, 1.41 and 1.43 respectively.
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Table I. Continued.
A, Studies published up to 2000
Area Population study Laboratory indications Health effects
Portoguesa, Sixty-five mothers living in three Mean serum TSH, thyroxin Long-term high dietary Se supply
Venezuela regions of different dietary Se and tri-iodo-thyronine were on the FT3 level in serum is
Brätter 1996 intake level were examined. in the normal range. Strong associated with the depression in
(106) The range of dietary Se range in regional differences for serum the activity of the selenoenzyme
 the Venezuelan seleniferous areas Se and FT3, but no effect iodo-thyronine-deiodinase (5 DI),
 is 250-980 µg/day. on the TSH and FT4 levels. which catalyzes the production
   of T3 from T4.
B, Studies published after 2000
Enshi, Hubei Fifteen villages from 3 Se  In the 5 HT villages were Despite the high concentrations
Province, China environments in Enshi district higher Se levels than NH  of Se found in the population
Fordyce 2000 were investigated. Soil, grain,  villages, with geometric mean of the HN and HT villages,
(107) drinking water and human hair of Se in soil of 9.46 µg/g,  no incidence of selenosis have
 samples were collected from in water of 32.6 µg/l been reported in recent years
 5 Low-Se-Keshan-Disease and in the hair of 26.4 µg/g. in Enshi District.
 villages (LK), 5 High-Se-No-
 toxicity (HN) villages, and 5 
 High-Se-Toxicity (HT) villages.
Yu Tang Ba,  Se was mainly present in the In 1999, Se in soil was Few people living in this area
Hubei Province,  carbonaceous shale (stone coal) 4.75±7.43 mg/kg. Se in stream experienced loss of hair and
China of this area. water was 58.4±16.8 µg/l. nails from early 1930s
Zhu 2001 (108)   to 1961. In 1963, 19 of 23
   local inhabitants manifested
   symptoms of Se poisoning.
Punjab, India Eighty subjects living in a Concentration of Se in the hair,  17.5% of men and 15% of women
Hira 2003 (109) seleniferous area compared to 80 nails and urine samples in the showed loss of hair and other Se
 controls living in non-seleniferous study group were higher than related symptoms like tooth decay
 area. Se intake in the endemic area control group. or black teeth.
 was 632±31.2 µg/day in men
 and 475±52.8 µg/day in women.
Nunavik, One hundred and two Canadian The average blood Se Neurotoxic signs, i.e. alterations
Northern Inuit children aged 5-6 years are concentration observed in the in visual evoked potentials with
Quebec, Canada involved in this study. The high present study was about the induction of longer latency
Saint-Amour consumption of fish and marine 5.6 mmol/l. Moreover, close to of some of these parameters.
2006 (27) mammals by this population 20% of the children tested had
 was associated to an unusually blood Se concentrations
 high intake of polychlorinated exceeding the maximum safe
 biphenyls, methyl-Hg, Se level recommended for
 and other potentially adults, which was from 8 to 
 neurotoxic substances.  10 mmol/l. Se umbilical
  blood level was 429 µg/l.
Lower Tapajos A study on 448 residents aged Median plasma Se level was These results appeared to disprove
River region 15-87 years in 12 communities.  135 µg/l. A direct association the detrimental effect of Se
(Parà state),  High level exposure to Se and between Se plasma levels exposure on motor exposure on
Brazil Hg in these population derived and motor performance motor functions, but could also
Lemire 2011 from the consumption of a Se-rich was found. be due to confounding such as
and 2012 diet of brazil nuts, fish species,   unmeasured heavy metals and
(110,111) meat and eggs.  other chemicals.
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Table I. Continued.
B, Studies published after 2000
Area Population study Laboratory indications Health effects
Shaanxi Seventy-one Keshan disease Blood selenium level was Patients (24, 25, 20 and 2 KD) had
Province,  (KD) patients were compared 0.065±0.016 µg/ml in NYHA class I, II, III, IV, 
China to 78 controls from the same KD patients and respectively. All controls had
Lei 2011 (20) endemic area and 212 external 0.086±0.020 µg/ml NYHA class I. A large number
 healthy controls from a in controls. GPx-1 activity of KD patients showed abnormal
 non-endemic area. was 73.002±12.623 U/g Hb) ECG, the most common disorders
  in KD patients and were conduction disorder and
  106.402±24.268 U/g Hb) cardiac load. All chronic KD
   in controls. patients showed cardiac dilation
   on echocardiography.
Enshi, Hubei Outbreak of human selenium Blood Se was 3248 µg/l. Unusual signs and symptoms
Province, China poisoning in the early 1960s. Se-rich  of Se poisoning were observed
Qin 2013 (112) carbonaceous rock was responsible  in this population. Neurological
 for high-Se content in soils, crops,   signs were found in 18 out
 water and thus human Se poisoning.   of 22 rural residents affected
 The calculated daily intake of  by severe selenosis: 
 Se was 2144 µg/day, cereal  acroparesthesia and dysestesia, 
 consumption is the major pathway  hyperreflexia, convulsions, motor
 of Se intake for local residents,  weakness and hemiplegia, 
 followed by vegetables, meats  polyneuritis.
 and drinking water.
Reggio Emilia,  From 1974 to 1985, 2065 Not assessed. Inorganic Se seemed to increase
Northern Italy municipal residents consumed  mortality from some site-specific
Vinceti 2013 and drinking water with high Se  cancers (melanoma, multiple
2016 (5,26) content approaching the  myeloma, lymphoid neoplasms as
 European standard of  well as colorectal and kidney cancer)
 10 µg/l in its inorganic  and neurodegenerative diseases
 hexavalent form (selenate).  like Parkinson's disease and ALS,
   while lower breast cancer mortality
   was found.
Macapà (Amapà Forty-one preschool children from Children from Belem Se intake of children from two cities
state) and Belem Macapà and 88 preschool from presented adequate was adequate but the inclusion
(Parà state), Belem were enrolled. The Brazilian plasma and erythrocytes  of Brazil nuts in Macapà diet
Brazil Amazon region is considered to levels, whereas the Macapà resulted in excess Se dietary
Martens 2015 have particularly Se-rich soil.  group had higher levels.  intake, although children from
(113) Brazil nuts are often used as a Also nails and hair were this city did not present symptoms
 strategy to improve Se status in more elevated in children of selenosis (i.e. changes to
 Se-deficient populations. This from Macapà. and loss of nails and hair, 
 study investigated Se intake and  skin lesions, unusual garlic
 Se status of children from Macapà  odor on the breath, nervous
 who received a Brazil nut-enriched  system defects).
 diet and compared with children
 from Belem where Brazil nut
 supplementation did not occur. Mean
 Se intake in Macapà diet: 155.30
 (range: 98.70-195.30) µg/day.
Punjab, India Human subjects (650) living Hair Se were 50.9±58.0 µg/g in Chronic exposure to high Se through
Chawla 2016 in a seleniferous area compared the exposed group compared the soil-plant water continuum
(114) to 50 healty controls from a to 22.5±10.7 µg/g in controls.  could place the human population
 village in a non-seleniferous area. Corresponding Se levels at risk of developing impaired
  (mean-SD) in nail clippings organ function.
  in the study and control
  groups were 154.0±91.5 µg/g
  and 117.4±49.8 µg/g.
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Studies in populations with ‘intermediate’ selenium status. 
Several studies have investigated the effects on human 
health of even limited changes in exposure to environmental 
selenium, which occurs through different environmental 
sources (primarily diet, but also air pollution, occupational 
environment, smoking and drinking water), in populations 
characterized by exposure levels not considered a priori to 
be unusually ‘low’ or ‘high’ (14). These studies, generally 
carried out in Western populations, have investigated a broad 
number of health outcomes, but in the majority of cases 
they focused on cancer risk (14,15). However, most of these 
studies had an observational design, thus suffering from the 
potential severe bias due to unmeasured confounding and 
exposure misclassification even in prospective cohort studies, 
in addition to the other biases typically effecting studies 
with case-control, cross-sectional and clearly ecologic 
design (1,14,29). In addition, their results have frequently 
been conflicting even for the same cancer type, as shown 
for instance for liver cancer (30,31), lung cancer (32-34) or 
breast cancer (35-38), though in most cases they supported 
the occurrence of an inverse relation between selenium 
status and cancer risk (1). Luckily and rather unexpectedly 
for a nutrient with also was known to exert a powerful 
toxicity, the nutritional interest in this metalloid as well as 
the extremely ‘attractive’ preliminary results of the first 
selenium trial carried out in Western countries, the Nutrition 
Prevention of Cancer (NPC) trial (39), a large number of 
randomized controlled trials have been conducted during 
the last two decades. The aim of these studies has been to 
investigate the effects on cancer risk of an increased intake 
of this element (1,40).
In Table II, we report the main features and results of 
these human studies with experimental design, including an 
assessment of the possible or established bias of this study 
based on our evaluation and the criteria developed within the 
Cochrane Collaboration network (41). In this overview, ‘old’ 
selenium trials carried out in China are also reported, but their 
scientific interest is very limited, if any, due to their very high 
risk of bias, as reported in detail in a previous assessment (1). 
Fortunately, these RCTs have generated a clear and consistent 
pattern of evidence about the effect of selenium on cancer risk, 
though partially unexpected given the underlying hypothesis 
which generated the trials, i.e. a beneficial effect of selenium 
on cancer risk (15). This is even more particularly with refer-
ence to the cancer type originally suggested by NPC to be 
most strongly associated with a beneficial effect of selenium, 
prostate cancer (39). In addition, these studies contributed in 
elucidating the relation between selenium and cardiovascular 
risk, another major issue of interest (42). Moreover, these trials 
have been fundamental in our understanding of the adverse 
effects of environmental selenium, rather unexpectedly 
since they encompassed supplementation of selenium doses 
considered a priori to be entirely safe (1,15). Therefore, and 
differently from other elements of comparable toxicity and of 
less nutritional interest, the risk assessment of environmental 
selenium has benefitted from the implementation of experi-
mental studies originally designed for a setting of potential 
selenium deficiency, but later found to be able to show and 
identify the early signs and symptoms related to the toxicity 
of this element.
Overall, all the recent trials have consistently shown that 
selenium does not modify risk of overall cancer, prostate 
cancer and other specific cancers (2,3,23,43-45), while it may 
even increase risk of cancers such as advanced (46,47) or 
overall prostate cancer (48), non-melanoma skin cancer (49,50) 
and possibly breast cancer in high-risk women (51). These 
results strongly and unexpectedly differ from the results 
reported in the earliest trial, the NPC (49,52), which however 
was small and more importantly was later found to be affected 
by a detection bias (53). As previously mentioned, these trials 
have also been of fundamental (and unforeseen) importance 
in identifying the early signs, symptoms and diseases asso-
ciated with chronic or subchronic selenium toxicity. In fact, 
they have shown that already at amount of selenium exposure 
(baseline dietary intake plus supplementation) of around 
250-300 µg/day there is an increased risk of type-2 diabetes. 
Such excess diabetes risk linked to selenium overexposure 
was first discovered in trial carried out in a population with a 
‘low’ baseline selenium status (15,22) and later confirmed in 
large trials (3,23). Finally, the largest of the selenium RCTs, 
SELECT (23), whose overall selenium intake in the supple-
mented group averaged 300 µg/day (15), has shown that such 
amount of exposure induces ‘minor’ adverse effects such as 
dermatitis and alopecia [a long-recognized sign of selenium 
toxicity (12)]. These effects indicate that the selenium lower-
observed-adverse-effect-level (LOAEL) is much lower than 
previously considered by regulatory agencies (5,54), which 
could base their assessment on the scarce data yielded by a few 
old Chinese environmental studies (55), calling for an update 
of the risk assessment of this element (5,15,56,57).
3. Adequacy of environmental standards
An issue therefore arises about the adequacy of current stan-
dards for environmental risk assessment of selenium in the 
human, for both abnormally low and high exposures. These 
standards have been defined by a number of agencies since 
2000 to 2014, and as summarized in Fig. 2 they encompass 
minimal recommended values ranging from 30 to 70 µg/day, 
and upper doses ranging from 300 to 400 µg/day (in adults) 
for overall selenium exposure (4,16,58-61). On the contrary, 
specific guidelines for single selenium species have not been 
unfortunately set, despite the clear evidence that the various 
chemical forms of selenium have different biological proper-
ties, i.e. nutritional and toxicological activities (7,9,10,62).
So far, the adequacy of the selenium standards has been 
mainly based on biochemical endpoints (for the lowest recom-
mended intake) and on the occurrence of adverse health 
outcomes (for the upper level), as identified in old studies 
carried out in seleniferous areas from China. However, the 
newly available data from the clinical trials indicate the need 
of a substantial reassessment of the dose of selenium toxicity, 
though they unfortunately do not allow to clearly identify a 
NOAEL and probably also a reliable LOAEL, since only one 
supplemental dose (200 µg/selenium/day) have been used in 
these trials and dose-response data are lacking. However, using 
an uncertainty factor as little as 3, i.e. lower that the uncertainty 
factors usually adopted in risk assessment (10 or more) also in 
light of the peculiar nature of this element and its nutritional 
relevance, selenium intake should not exceed 90 µg/day taking 
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into account the signs of toxicity yielded by the NPC trial (an 
excess diabetes and skin cancer risk) and by the SELECT trial 
(an excess incidence of diabetes, advanced prostate cancer, 
dermatitis and alopecia) (1), as shown in Fig. 2. However, 
this estimate may be still inadequate to protect human health 
from chronic selenium toxicity, and in addition it appears to 
apply only to organic selenium, and to selenomethionine in 
particular [whose toxicity has bene recently much better eluci-
dated (63-65)]. 
For inorganic selenium, typically selenate such as those 
found in underground and drinking waters, the epidemiologic 
evidence points to a much higher toxicity compared with 
organic selenium and exactly as expected on the basis of 
experimental studies (10), therefore suggesting much lower 
acceptable environmental standards (57), tentatively 1 µg/l for 
drinking water (5). New standards should also be considered 
for occupational exposure to selenium, given the limited 
data available and the potential for toxicity of this source of 
exposure (12,13,66,67). Finally, air selenium might represent 
a so far overlooked risk factor for chronic diseases, taking 
into account that its outdoor air concentrations have been 
positively associated with cardiovascular mortality (68) and 
with childhood leukemia risk (69), though more evidence is 
clearly required to confirm such possible associations mainly 
due to the inherent risk of unmeasured confounding in these 
observational studies.
The lowest acceptable amount of selenium exposure is 
instead much more controversial and uncertain. Two approaches 
have been used to define such lowest safe level of exposure: 
the proteomic change induced by the trace element, and the 
avoidance of adverse health effects. Concerning the latter 
point (health issues), still limited and inconclusive evidence is 
available on the large number of diseases tentatively ascribed 
to a deficiency of environmental selenium (4,70), such as the 
chronic degenerative osteoarthropathy with unclear etiology 
named ‘Kashin-Beck’ disease (71,72) and an increased suscep-
tibility to viral infections (73,74). 
In addition, the hypothesis of an effect of ‘low’ environ-
mental selenium exposure in increasing cancer risk may now 
be ruled out, thanks to the consistent evidence yielded by the 
recent large and well-conducted randomized trials, which 
ruled out any preventive effect of selenium on cancer risk. On 
the converse, evidence exists on the involvement of selenium 
deficiency on the etiology of a rare but severe cardiomy-
opathy named Keshan disease and endemic in some Chinese 
areas (17,18,20,75-77), and this observation has played a key 
role in the identification of the minimal amount of selenium 
which appears to be required in humans (4,78). Such involve-
ment has been suggested mainly on the basis of observational 
evidence, i.e. a lower selenium status in the populations more 
affected by this disease, and following the beneficial effects of 
a selenium supplementation trial on disease incidence. 
Figure 2. Comparison between environmental and dietary upper and lower standards for selenium (left) and the thresholds of adverse health effects of selenium 
(right) using an uncertain factor of 3 (dark grey) and of 10 (light gray). Data refer to daily overall selenium dietary intake.
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Table II. Overview and main details of the randomized controlled trials with selenium supplementation in cancer prevention.
    Median
   Type of Se follow-up Risk of
Trial Region Populationa supplement or duration bias Main results
PLC prevention in China 130471 (20847/109624) Se-salt tablet with Up to 5 years Very Reduction of PLC incidence
general population  Subjects at high 15 ppm anhydrous  high in township treated respect
(115,116)  risk to PLC sodium selenite  risk other four placebo treated
PLC prevention in China 226 (113/113) Subjects 200 µg/day Up to 4 years Very 0 and 5 PLC cases in
HBsAg carriers  HBsAg carriers selenized yeast  high Se supplement
(116,117)  in area with high   risk and placebo arms, 
  PLC incidence    respectively
PLC prevention in China 2474 (1444/1030) 200 µg/day Up to 2 years Very PLC: RRb 0.55
members of  Members of families selenized yeast  high (95% CI 0.22-1.35)
families with high  with high incidence   risk
PLC incidence  of PLC
(116)
PLC prevention in China 3849 (2364/1485) 200 µg/day Up to 2 years Very PLC: RRb 0.39
members of  Members of families selenized yeast  high (95% CI 0.10-1.36)
families with high  with high incidence   risk
PLC incidence  of PLC
(117)
PLC prevention in China 2065 (1112/953) 0.5 mg sodium Up to 3 years Very PLC: RRb 0.51
HBsAg carriers  Subjects HBsAg selenite tablet  high (95% CI 0.32-0.80)
(118)  carriers in area with   risk
  high PLC incidence
NPC - Nutritional USA 1250 (621/629) in 2002 200 µg/day high- Mean 7.9 years High Any cancer: HR 0.75
Prevention of  Subjects with history high-selenium up to 13 years risk (95% CI 0.58-0.97)
Cancer study  of basal or squamous yeast (end of blinded  Bladder cancer: HR 1.28
(49,52)  cell skin cancer  period)  (95% CI 0.50-3.25)
      Breast cancer: HR 1.89
      (95% CI 0.69-5.14)
      Colorectal cancer: HR 0.46
      (95% CI 0.21-1.02)
      Lung cancer: HR 0.74
      (95% CI 0.44-1.24)
      Melanoma: HR 1.18
      (95% CI 0.49-2.85)
      NMSC: HR 1.17
      (95% CI 1.02-1.34)
      Prostate cancer: HR 0.48
      (95% CI 0.28-0.80)
Organ transplant France 184 (91/93) 200 µg/day Up to 5 years High Skin keratoses: RRb 1.09
recipients (50)  Organ graft (liver,  selenium enriched (3 of treatment risk (95% CI 0.65-1.84)
  kidney or heart)  yeast and 2 only of  Skin cancers: RRb 3.07
  recipients aged 18-65  follow-up)  (95% CI 0.55-31.06)
SELECT -  USA,  17448 (8752/8696) 200 µg/day Median Low Any cancer: HR 1.01
Selenium and Canada Healthy men  selenized yeast/ 5.46 years risk (99% CI 0.89-1.15)
Vitamin E Cancer and ≥50 years, l-selenomethionine   Bladder cancer: HR 1.13
Prevention Trial Puerto not suspicious    (99% CI 0.78-1.63)
(2,23,119,120) Rico for cancer    Colorectal cancer: HR 1.05
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Table II. Continued.
    Median
   Type of Se follow-up Risk of
Trial Region Populationa supplement or duration bias Main results
  at digital rectal    (99% CI 0.66-1.67)
  examination    Lung cancer: HR 1.12
      (99% CI 0.73-1.72)
      Prostate cancer: HR 1.04
      (99% CI 0.87-1.24)
      Cardiovascular events: 
      HR 1.07 (99% CI 0.94-1.22)
BRCA1 carriers Poland 1,135 Women 250 µg/day Median Not Any cancer: HR 1.4
(51)  BRCA1 carriers inorganic 2.92 years evaluable (95% CI 0.9-2.0)
   selenite   Breast cancer: HR 1.3
      (95% CI 0.7-2.5)
SWOG (Southwest USA 423 (212/211) Men 200 µg/day Up to Low Prostate cancer: RR 0.97
Oncology Group)   aged ≥40 years with selenium 3 years risk (95% CI 0.68-1.39)
Trial S9917 (121)  biopsy-confirmed
  diagnosis of HGPIN
  but cancer free
NBT - Negative USA 699 (467/232) 234 with Median Low Any cancer: RRb 0.98
Biopsy Trial (44) and Men aged <80 years 200 µg/day 3 years risk (95% CI 0.64-1.52)
 New at high risk for and 233 with Up to  Colon cancer: RRb 0.99
 Zealand prostate cancer,  400 µg/day 5 years  (95% CI 0.05-58.62)
  negative for selenized yeast   Melanoma: RRb 1.24
  cancer or HGPIN    (95% CI 0.20-13.04)
      NMSC: RRb 0.57
      (95% CI 0.35-0.95)
      Prostate cancer: RRb 0.98
      (95% CI 0.64-1.52)
Eastern USA 1,561 (1040/521) 200 µg/day Up to Low Secondary primary tumors:
Cooperative  Adult subjects with selenized yeast 4 years risk Any cancer: RRb 1.02
Oncology Group  resected Stage I    (95% CI 0.78-1.34)
(ECOG) Trial 5597  Non-small cell    Bladder cancer: RRb 0.75
(45)  lung cancer    (95% CI 0.24-2.67)
      Colonrectal cancer: RRb 0.50
      (95% CI 0.09-2.69)
      Lung cancer: RRb 1.26
      (95% CI 0.77-2.15)
      Melanoma: RRb 1.25
      (95% CI 0.21-13.15)
      NMSC: RRb 0.70
      (95% CI 0.36-1.35)
      Prostate cancer: RRb 0.89
      (95% CI 0.37-2.29)
Selenium and USA 1,374 (685/689) 200 µg/day Median Low Any adenoma: RR 1.03
Celecoxib  subjects aged selenized yeast 2.96 years risk (95% CI 0.91-1-16)
(Sel/Cel)  40-80 years following    Advanced adenoma: 
Trial (3)  colonoscopic removal    RR 1.02 (95% CI 0.74-1.43)
  of colorectal adenomas    Multiple (≥3) adenoma: 
      RR 1.47 (95% CI 1.08-2.02)
      Squamous cell ca: RR 1.34
      (95% CI 0.76-2.37)
HBsAg, hepatitis B virus surface antigen S; HGPIN, high-grade prostatic intraepithelial neoplasia; PLC, primary liver cancer; NMSC, non-melanoma 
skin cancer; NR, not reported; SPC, secondary primary cancer. aNumber of total subjects in the trial (treatment/placebo) and study description. bCom-
puted using the ‘iri’ routine of STATA 14.1 (Stata Corp., College Station, TX, USA).
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However, some epidemiologic features of the disease 
have since the discovery of the disease suggested alternative 
etiologic hypotheses (79), particularly a cardiotropic infec-
tious agent such as a Coxsackie virus, selenium deficiency 
possibly being a cofactor in disease etiology or simply 
an innocent bystander (19,20,54,77). Under this perspec-
tive, the beneficial effect of selenium supplementation in 
a Chinese trial might be interpreted as an indication of 
antiviral effects of the selenium compound used (inorganic 
tetravalent selenium, i.e. selenite), as suggested by labora-
tory studies (40,80). In any case, while still investigating 
the cause of Keshan disease and the possible involvement 
of selenium status, it is prudent to avoid a too low intake of 
selenium under the hypothesis of a role in Keshan disease 
etiology, and therefore average population intake must be 
higher than that shown to be required to avoid disease inci-
dence, i.e. 13.3 µg/day in females and 19.1 in males (16). 
Finally, recent evidence has suggested adverse health effects 
of mutations affecting Sec insertion sequence-binding 
protein 2 or the selenoprotein N1 gene (81-83), though such 
abnormalities might not be strictly related to a ‘selenium 
deficiency’ neither were they corrected by its supplemen-
tation (84), thus being of limited interest in the setting of 
minimal dietary selenium requirements.
Alternatively, to the use of health endpoints, and consider-
ably more frequently, the amount of the selenium needed to 
induce the maximization of selenoprotein synthesis (particu-
larly glutathione-peroxidase and plasma seleno protein P) has 
been proposed to set the minimal requirement of selenium in 
the human. This approach has been based on the assumption 
that achievement of this biochemical endpoint, i.e. upregula-
tion (frequently defined as ‘optimization’) of selenoprotein 
synthesis indicates the achievement of an adequate supply of 
this trace element to the human (40,85). This would point to 
adequate dietary intake (considering this as only source of 
selenium exposure) of amount in the order of 70 µg/day (85), 
thus reaching or even exceeding the upper limit definable on 
the basis of the SELECT trial results using an uncertainty 
factor of 3 and clearly even more, of course, when using an 
uncertainty factor of 10 (Fig. 2). In addition, this ‘biochemical’ 
approach does not take into account that selenoprotein maxi-
mization which follows selenium species administration may 
derive not just from the ʻcorrection’ of a nutritional deficiency 
of the trace element, but as a compensatory response of these 
proteins (all characterized by antioxidant properties) to the 
pro-oxidant activity of selenium species (40,54,86-94). 
There is also little evidence showing that selenoprotein 
activity, and particularly its maximization, are beneficial 
to human health, and therefore (as more generally levels for 
antioxidant enzymes) this should not be regarded as an objec-
tive unless more evidence in humans are provided (40,54). 
This approach is further strengthened when taking into 
account that these enzymes are physiologically induced and 
inducible by oxidative stress (for selenoproteins, even in the 
absence of any change in selenium supply) (40,54), as long 
recognized since the discovery of the selenium-containing 
antioxidant enzyme glutathione-peroxidase (95-97). Overall, 
it seems therefore prudent to avoid a maximal expression of 
selenoproteins (54,98), setting as standard a lower amount of 
their activity, such as proposed by WHO when suggesting a 
‘nutritionally adequate’ target (‘recommended nutrient intake’) 
the achievement of two thirds of the maximal selenoprotein 
activity, corresponding to a daily selenium intake of 25-34 µg 
in adults (Fig. 2). However, more research is clearly required 
to set reliable lower and upper safe selenium levels, though the 
current standards need to be quickly updated with reference 
to the upper levels taking into account the above-mentioned 
recent results of the epidemiologic studies, i.e. the high-quality 
RCTs and the environmental studies, and also considering the 
opportunity to set species-specific standards for this element.
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